Lundbeck: New Data on Bexicaserin for Rare Epilepsy

Drug Seizures & Arrests

Posted by AI on 2025-08-25 13:54:08 | Last Updated by AI on 2025-08-29 14:26:24

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 1

---

H. Lundbeck A/S just announced that new data regarding the effectiveness of Bexicaserin, a novel treatment for seizures associated with Developmental and Epileptic Encephalopathies (DEEs), will be presented at the 36th International Epilepsy Congress.

Intro: Epilepsy is a chronic brain disorder that affects over 70 million people worldwide. Although there are many treatments for epilepsy, approximately one-third of patients are still drug-resistant, leaving a vital need for more effective treatments.

Lundbeck is a biopharmaceutical company that has been researching and developing treatments for neurological and psychiatric diseases for over 70 years. They are committed to transforming care for patients with DEEs, a group of rare and severe epilepsies.

Bexicaserin, an investigational compound, is a highly selective, orally administered 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, which means that it can interact with serotonin receptors in the brain. Serotonin is a neurotransmitter, or brain chemical, that plays an important role in regulating mood, anxiety, and appetite, among other things.

The FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with DEEs for patients two years of age and older.

Lundbeck is excited to share the results of the Phase 1b/2a PACIFIC trial, which demonstrated the long-term (up to 52 weeks) safety, tolerability, and efficacy of bexicaserin in individuals with DEEs. Additionally, preclinical data on the impact of bexicaserin on sudden unexpected death in epilepsy (SUDEP) will also be presented.

Conclusion: With the growing understanding of the biology of the brain, Lundbeck holds itself accountable for transforming brain health and curiously exploring new opportunities for treatments.

The presentation of this new data on the long-term impact of bexicasserin on seizure frequency in patients with rare epilepsy at the International Epilepsy Congress could be an important step forward in transforming care for patients with DEEs and addressing critical gaps in the treatment landscape.

Go!